166 related articles for article (PubMed ID: 12063979)
1. Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels.
Miyaguchi S; Watanabe T; Takahashi H; Nakamura M; Saito H; Ishii H
Hepatogastroenterology; 2002; 49(45):724-9. PubMed ID: 12063979
[TBL] [Abstract][Full Text] [Related]
2. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus.
Shiratori Y; Shiina S; Teratani T; Imamura M; Obi S; Sato S; Koike Y; Yoshida H; Omata M
Ann Intern Med; 2003 Feb; 138(4):299-306. PubMed ID: 12585827
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.
Chen LT; Chen MF; Li LA; Lee PH; Jeng LB; Lin DY; Wu CC; Mok KT; Chen CL; Lee WC; Chau GY; Chen YS; Lui WY; Hsiao CF; Whang-Peng J; Chen PJ;
Ann Surg; 2012 Jan; 255(1):8-17. PubMed ID: 22104564
[TBL] [Abstract][Full Text] [Related]
4. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
5. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group.
Lancet; 1998 May; 351(9115):1535-9. PubMed ID: 10326535
[TBL] [Abstract][Full Text] [Related]
6. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
7. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus.
Hung CH; Lee CM; Wang JH; Tung HD; Chen CH; Lu SN
J Gastroenterol Hepatol; 2005 Oct; 20(10):1553-9. PubMed ID: 16174073
[TBL] [Abstract][Full Text] [Related]
8. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
[TBL] [Abstract][Full Text] [Related]
9. Transcatheter arterial chemoembolization therapy combined with percutaneous ethanol injection for unresectable large hepatocellular carcinoma: an evaluation of the local therapeutic effect and survival rate.
Dohmen K; Shirahama M; Shigematsu H; Miyamoto Y; Torii Y; Irie K; Ishibashi H
Hepatogastroenterology; 2001; 48(41):1409-15. PubMed ID: 11677976
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma.
Li M; Lu C; Cheng J; Zhang J; Cao C; Xu J; Xu J; Pan H; Zhong B; Tucker S; Wang D
J Gastroenterol Hepatol; 2009 Aug; 24(8):1437-44. PubMed ID: 19486255
[TBL] [Abstract][Full Text] [Related]
11. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.
Mazzaferro V; Romito R; Schiavo M; Mariani L; Camerini T; Bhoori S; Capussotti L; Calise F; Pellicci R; Belli G; Tagger A; Colombo M; Bonino F; Majno P; Llovet JM;
Hepatology; 2006 Dec; 44(6):1543-54. PubMed ID: 17133492
[TBL] [Abstract][Full Text] [Related]
12. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
13. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.
Lo CM; Liu CL; Chan SC; Lam CM; Poon RT; Ng IO; Fan ST; Wong J
Ann Surg; 2007 Jun; 245(6):831-42. PubMed ID: 17522506
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation.
Sheiner PA; Boros P; Klion FM; Thung SN; Schluger LK; Lau JY; Mor E; Bodian C; Guy SR; Schwartz ME; Emre S; Bodenheimer HC; Miller CM
Hepatology; 1998 Sep; 28(3):831-8. PubMed ID: 9731580
[TBL] [Abstract][Full Text] [Related]
15. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Reed A; Hemming A; Howard R; Van Der Werf W; Lauwers G; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2002 Nov; 8(11):1000-6. PubMed ID: 12424712
[TBL] [Abstract][Full Text] [Related]
16. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
Keeffe EB; Hollinger FB
Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
[TBL] [Abstract][Full Text] [Related]
17. [Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment].
Pérez Roldán F; De Diego A; Casado M; Matilla A; Bañares R; García-Durán F; Salcedo M; Cos E; Clemente G
Rev Esp Enferm Dig; 1996 Sep; 88(9):609-15. PubMed ID: 8962775
[TBL] [Abstract][Full Text] [Related]
18. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.
Mazzella G; Accogli E; Sottili S; Festi D; Orsini M; Salzetta A; Novelli V; Cipolla A; Fabbri C; Pezzoli A; Roda E
J Hepatol; 1996 Feb; 24(2):141-7. PubMed ID: 8907566
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
Scand J Gastroenterol; 2005 Jun; 40(6):688-96. PubMed ID: 16036529
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
